Nanobiotix S.A. (NNBXF)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
At close: 02:47PM EST
| Previous close | 9.10 |
| Open | 9.10 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 9.10 - 9.10 |
| 52-week range | 7.32 - 19.85 |
| Volume | |
| Avg. volume | 64 |
| Market cap | N/A |
| Beta (5Y monthly) | 2.31 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.64 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
PARIS, January 11, 2022--Regulatory News: Nanobiotix (Paris:NANO) (NASDAQ:NBTX):
- Business Wire
NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets
PARIS & CAMBRIDGE, Mass., January 10, 2022--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today provided a corporate update highlighting key priorities and anticipated development milestones for 2022.
- Investing.com
Nanobiotix Rallies After Enrolling First Patient in Head and Neck Cancer Treatment
By Sam Boughedda
© 2022 Yahoo. All rights reserved.
